Baker Bros. Advisors LP Xenon Pharmaceuticals Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 370,208 shares of XENE stock, worth $16.1 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
370,208
Previous 347,408
6.56%
Holding current value
$16.1 Million
Previous $11.7 Million
0.58%
% of portfolio
0.12%
Previous 0.14%
Shares
7 transactions
Others Institutions Holding XENE
# of Institutions
223Shares Held
72.7MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$235 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$188 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$157 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$155 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$138 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.7B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...